The study included 121 patients who were either high risk for CRC or presented with CRC symptoms. Of these patients, 23 were found to have CRC.
The panel test of four NuQ biomarker assays detected 91 percent of CRC with 90 percent specificity.
“Moreover, 87% of colorectal cancer cases and 67 percent of high-risk dysplastic pre-cancerous polyps were detected using an unadjusted panel of five NuQ assays alone, and no patient information. The study data provide evidence of the significant potential of our diagnostic NuQ tests for detecting colorectal cancer,” said Jake Micallef, PhD, VolitionRx’s chief scientific officer.
More articles on gastroenterology:
A day in the life: 24 statistics on how gastroenterologists spend their time
5 most-read GI/endoscopy stories: Week of Nov. 30 – Dec. 4
FDA clears 5 GI/endoscopy devices in November
